Pseudomonas aeruginosa

Overview

Pseudomonas aeruginosa is a Gram-negative bacterium and a major opportunistic pathogen of clinical importance. It is widely recognized for its intrinsic and acquired antimicrobial resistance, its ability to form biofilms, and its persistence in hospital and community settings. These traits make it a frequent cause of difficult-to-treat infections, particularly in intensive care units, burn and wound infections, chronic lung disease, and other settings where host defenses are compromised.

Biologically, P. aeruginosa is notable for its adaptability to hostile environments, including antibiotic exposure, mechanical confinement, and polymicrobial communities. Recent studies highlighted in the provided contexts emphasize its role as a carbapenem-resistant and multidrug-resistant pathogen, its involvement in chronic cystic fibrosis lung infection, and its capacity to co-colonize with organisms such as Staphylococcus aureus, Candida albicans, Escherichia coli, Acinetobacter baumannii, and Haemophilus influenzae. Because of these features, it is a major target for research into biofilm disruption, quorum sensing inhibition, novel antimicrobials, wound dressings, nanomaterials, and improved diagnostic assays.

Focus of Latest Publications

Recent investigations have demonstrated diverse therapeutic approaches targeting P. aeruginosa infections through advanced biomaterial and nanotechnology platforms. Multiple studies evaluated nanoparticle-based systems for infected wound management, including silver nanoparticles (AgNPs), zinc oxide nanoparticles (ZnONPs), selenium nanoparticles (SeNPs), and ruthenium-based nanozymes, either alone or incorporated into hydrogel matrices. These materials achieved rapid and potent antibacterial activity, with silver nanoparticles demonstrating >10 log₁₀ CFU/mL reduction against P. aeruginosa within 2–6 hours and achieving 99.9% bacterial eradication in certain formulations. Photothermal hydrogels incorporating 808 nm near-infrared (NIR) irradiation combined synergistic mechanisms—hyperthermia-induced membrane damage, reactive oxygen species generation, and biofilm disruption—to achieve comparable eradication rates. In in vivo wound infection models, these platforms accelerated healing, reduced bacterial burden to 0.5–1% of untreated controls, and promoted tissue regeneration through enhanced angiogenesis and collagen deposition while maintaining favorable biocompatibility profiles.

Natural products and botanical extracts have emerged as alternative antimicrobial sources, with investigations focusing on phytochemicals and quorum sensing inhibition as mechanisms distinct from conventional antibiotic resistance. Essential oils from Thymus vulgaris, Rosmarinus officinalis, and Lavandula angustifolia containing carvacrol, linalool, and camphor demonstrated notable antibiofilm activity, with T. vulgaris oil achieving 7 log-unit reductions in P. aeruginosa biofilms at 2× minimum inhibitory concentration (MIC). Phytochemical compounds including kaempferide from Alpinia officinarum (MIC 0.024 mg/mL), extracts from Ocimum basilicum varieties, and anti-quorum sensing molecules isolated from Myristica fragrans (nutmeg) showed antibacterial activity through membrane disruption and inhibition of bacterial cell-to-cell communication pathways. Horseradish (Armoracia rusticana) was investigated as a source of quorum sensing inhibitors to attenuate P. aeruginosa virulence through ethnomedicinal applications.

P. aeruginosa continues to present significant therapeutic challenges through the development and transmission of multidrug resistance. Genomic studies tracking within-patient evolution during antimicrobial therapy revealed that single strains accumulate resistance-associated mutations in genes including ampC, ftsI, and mexR over time, with metagenomic analysis detecting resistance variants at low frequencies that subsequently rise to fixation following treatment. Clinical surveillance in an intensive care unit reported 30.7% multidrug-resistant prevalence, with resistance rates reaching 46.3% by 2024, alongside elevated resistance to newer agents (ceftazidime-avibactam 29.8%, ceftolozane-tazobactam 26.2%). Mechanistically, confined growth conditions—such as those encountered in biofilms, tissues, or hydrogels—enhanced P. aeruginosa tolerance to antibiotics through sodium-proton antiporter-mediated active efflux and protective membrane remodeling, independent of intrinsic genetic resistance.

Novel diagnostic and immunological approaches have advanced detection capabilities for P. aeruginosa infections. A trimetallic nanozyme (D-PtPdOs) engineered through ligand-mediated charge transfer was integrated into enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA) platforms, achieving 14.58-fold and 250-fold sensitivity enhancements over conventional horseradish peroxidase-based detection, with machine learning algorithms enabling high-precision quantification in complex blood samples. Magnetic fluorescent probe-based multiplex immunochromatographic assays (GFDQD@Si) enabled concurrent bedside detection of P. aeruginosa alongside sepsis biomarkers (procalcitonin, interleukin-6) with bacterial limits of detection at 7 CFU/mL, demonstrating rapid, sensitive diagnosis in clinical blood samples. P. aeruginosa was also identified as a primary bacterial co-colonizer in aspergilloma biofilms from chronic pulmonary aspergillosis patients, where it engaged in metabolic cross-feeding and antagonistic inter-kingdom interactions with Aspergillus fumigatus, contributing to treatment resistance and disease chronicity.